Related Experiment Video
Updated: Mar 18, 2026
10:37
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
8.7K
[IRRITABLE BOWEL SYNDROME. NEW HORIZONS]
Anales De La Real Academia Nacional De Medicina
|July 13, 2016
Summary
Irritable bowel syndrome (IBS) is a chronic disorder influenced by gut microbiota changes. Understanding host-microbiota interactions offers new therapeutic avenues for IBS management.
Area of Science:
- Gastroenterology and Microbiology
- Focuses on the gut microbiota and its role in chronic disorders.
Context:
- Irritable bowel syndrome (IBS) is a complex chronic condition.
- Factors like infections, antibiotic use, and bowel cleansing can alter gut microbiota composition.
- The intricate relationship between the host, microbiota, immune system, and enteric nervous system is crucial for IBS pathophysiology but not fully understood.
Purpose:
- To explore the significance of host-microbiota interactions in understanding IBS pathogenesis.
- To identify potential therapeutic strategies for modulating the gut microbiota in IBS patients.
Summary:
- Investigates the complex origins of irritable bowel syndrome (IBS), highlighting the impact of factors affecting gut microbiota.
- Emphasizes the importance of understanding host-microbiota interactions for elucidating IBS pathogenesis.
- Discusses emerging therapeutic options including prebiotics, probiotics, novel analgesics, antibiotics like rifaximin, and fecal microbiota transplantation.
Impact:
- Advances the understanding of gut microbiota's role in gastrointestinal disorders.
- Suggests novel therapeutic strategies for irritable bowel syndrome (IBS) management.
- Highlights fecal microbiota transplantation as a potential future treatment for IBS.
Related Concept Videos
01:17Irritable Bowel Syndrome I: Introduction
1.4K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.4K
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
1.0K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
1.0K
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
961
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
961
01:17Drugs for Treatment of Diarrhea-Predominant IBS
849
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
849
01:17Chronic Bowel Disorders: Introduction
891
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
891
01:21Drugs for Treatment of Constipation-Predominant IBS
1.1K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.1K